For almost 10 years now the TNI medical AG does research and development in medical devices for a side effect free respiration therapy for patients with COPD, fibrosis or ILD. Being launched in March 2015, the TNI softFlow 50 systems ensure the latest findings for a side-effect free, high quality, safe and easy to use ventilation treatment for clinical and home care use. In fall 2016 the product range will be extended with the TNI softFlow junior for the treatment of prematures, neonatals and infants.
Therapy with Nasal Insufflation supplies the patient with an accurate flow and humidity regulated, warm air flow, if necessary combined with oxygen, by a very thin sound optimized heated nasal prong applicator. This leads to an improvement of ventilation with a high therapy acceptance and excellent patient outcome.
“Our long lasting active research work resulted in consequent enhancements of our TNI systems”, emphasizes Ewald Anger, CEO of TNI medical AG.
The results of the research have been presented exclusively at the DGP congress in Leipzig this year. Renowned pneumologists reported about clinical application fields, as well as the effectiveness of Nasal Highflow (find the gleanings on www.tni-medical.de). The brisance of this topic becomes clear, while worldwide 10 percent of the total population is suffering from COPD which is one of the most fast growing diseases and an enormous challenge for all health care systems worldwide. Current standards treating these patients in home care have significant problems and disadvantages. TNI medical AG is targeting a cost effective therapy which is adapted to the patients needs individually.
“With our new TNI softFlow systems we are able to comply clinical requirements and to continue the following homecare therapy identically and safe”.
Ewald Anger Cell: 0160 90193157
TNI medical AG Phone: +49 931 207929 02
Hofmannstraße 8 Fax: +49 931 207929 18
D- 97084 Wuerzburg Email: firstname.lastname@example.org